Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679456 | 1.00 | TSHR (0.34) | TSHRATMPPP5CALDH1A1NPSR1 | |
| SCHEMBL2679454 | 1.00 | TSHR (0.34) | TSHRATMPPP5CALDH1A1NPSR1 | |
| SCHEMBL20738512 | 0.82 | ATM (0.50) | TSHRATMALDH1A1NPSR1KDM4E | |
| SCHEMBL4915983 | 0.78 | — | — | |
| SCHEMBL4915987 | 0.78 | — | — | |
| SCHEMBL23573431 | 0.77 | ATM (0.36) | TSHRATMALDH1A1KDM4ELMNA | |
| SCHEMBL18793891 | 0.77 | MTNR1A (0.39) | TSHR | |
| SCHEMBL2116961 | 0.76 | TFPI2 (0.37) | TSHRATMKDM4ELMNAPPP1CA | |
| SCHEMBL15914391 | 0.76 | TFPI2 (0.37) | TSHRATMKDM4ELMNAPPP1CA | |
| SCHEMBL15914393 | 0.76 | TFPI2 (0.37) | TSHRATMKDM4ELMNAPPP1CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | TSHR 4076/4885ATM 412/4885PPP5C 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.